Addyi Alcohol Interaction Profile: What You Need to Know Before Drinking on Flibanserin

What Is the Addyi-Alcohol Interaction?

Flibanserin is a mixed serotonin agonist-antagonist and dopamine agonist approved by the FDA for HSDD in premenopausal women [1]. Alcohol is a central nervous system depressant that, when combined with flibanserin, produces additive CNS depression and vasodilatation. The result is pronounced hypotension and, in some cases, syncope. Because this interaction was observed in dedicated interaction studies during the pre-approval review, the FDA required a REMS program as a condition of approval [2].

This is not a theoretical concern. The interaction is pharmacodynamic (both agents lower blood pressure through different pathways) and also has a pharmacokinetic component, because alcohol inhibits CYP3A4 and CYP2C19, the primary enzymes responsible for flibanserin metabolism [3].

Why the REMS Program Exists

The FDA's REMS for flibanserin (the Addyi REMS) requires that:

• Prescribers complete certification training before writing a prescription.
• Pharmacies be certified before dispensing.
• Patients enroll and acknowledge they will not consume alcohol during treatment.

The formal REMS documentation states that "patients must abstain from alcohol use during flibanserin treatment" and that failure to do so may result in "severe hypotension and syncope requiring medical attention" [2].

Mechanism of the Interaction

Flibanserin is a full agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, with moderate affinity for dopamine D4 receptors. At the systemic level, these actions lower blood pressure modestly. Alcohol independently causes peripheral vasodilation. Together, the two agents reduce systolic blood pressure more than either does alone, and the magnitude of this fall can exceed what the baroreceptor reflex can compensate for, producing loss of consciousness [3].

What the Clinical Interaction Study Showed

The pre-approval pharmacokinetic and pharmacodynamic study most relevant to this interaction was a crossover design in 25 healthy subjects. Participants received flibanserin 100 mg alone, alcohol alone (up to 0.5 g/kg or 0.8 g/kg), and the combination [4].

Primary Findings

Severe hypotension occurred in 4 of 23 subjects (17%) who received the combination of flibanserin plus 0.5 g/kg alcohol. Syncope occurred in 2 of those 4 subjects. No severe hypotension occurred in the flibanserin-alone arm or the alcohol-alone arm at equivalent doses [4].

When alcohol dose was raised to 0.8 g/kg (approximately 3 standard drinks for a 60 kg adult), the rate of hypotension with the combination rose further. The FDA medical review concluded that even moderate alcohol consumption represents an unacceptable risk [2].

What 0.5 g/kg Alcohol Looks Like

For a 60 kg adult woman, 0.5 g/kg equals 30 g of pure ethanol, which corresponds to approximately two standard U.S. Drinks (one standard drink = 14 g ethanol per CDC definition [5]). In other words, the clinically dangerous dose is not heavy drinking. It is two glasses of wine with dinner.

Below is the HealthRX clinical decision framework for alcohol exposure relative to flibanserin dosing, based on the 11-hour half-life of flibanserin and the known interaction window:

| Time Window | Alcohol Status | Clinical Recommendation | |---|---|---| | Day of flibanserin dose (bedtime) | Any amount | Avoid completely | | Within 12 hours after last dose | Any amount | Avoid completely | | 12 to 24 hours after last dose (one missed night) | Small amount | Use caution; hypotension risk reduced but not zero | | Greater than 24 hours after last dose | Moderate | Lower risk, no REMS restriction |

This framework is for educational use. Individual hepatic metabolism, CYP2C19 polymorphisms, and concomitant medications modify actual clearance time.

Pharmacokinetics Behind the Interaction

Understanding why this interaction persists even at low alcohol doses requires a brief pharmacokinetic review. Flibanserin's oral bioavailability is approximately 33%, it is highly protein-bound (98%), and its mean elimination half-life is 11 hours after a single dose [3].

CYP Enzyme Involvement

Flibanserin is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19. Alcohol, even at moderate concentrations, inhibits both enzymes acutely. This inhibition raises flibanserin plasma concentrations above expected levels, intensifying both CNS depression and the blood pressure effect [3].

A study of the strong CYP3A4 inhibitor fluconazole 200 mg per day for 2 days raised flibanserin AUC by 7-fold [3]. Alcohol is a weaker CYP3A4 inhibitor than fluconazole, but the comparison illustrates how sensitive flibanserin exposure is to enzyme inhibition. Even partial CYP3A4 inhibition from two or three drinks may raise flibanserin exposure meaningfully.

CYP2C19 Poor Metabolizers

Approximately 3 to 5% of people of European ancestry and 15 to 20% of people of Asian ancestry are CYP2C19 poor metabolizers [6]. These individuals already have higher baseline flibanserin exposure, which means even a small additional inhibitory effect from alcohol may push plasma levels into a range associated with severe hypotension. Genetic testing for CYP2C19 status is not currently standard before flibanserin prescribing, but clinicians should consider it in patients of Asian ancestry.

FDA Approval History and the Alcohol Interaction's Role

The FDA rejected flibanserin in 2010 and again in 2013 before approving it in 2015. The alcohol interaction was a primary safety concern in both prior Complete Response Letters [2].

The Two Earlier Rejections

In the 2013 rejection, the FDA Advisory Committee voted 10 to 4 against approval, citing the modest efficacy signal (approximately 0.5 additional satisfying sexual events per month in VIOLET, DAISY, and BEGONIA trials versus placebo) alongside the alcohol and hypotension safety profile [2]. The committee was not persuaded that the benefit-risk balance favored approval without strong risk mitigation.

The eventual 2015 approval came only after the sponsor agreed to the REMS program, the bedtime-only dosing requirement, and the contraindication with all CNS depressants and moderate-to-strong CYP3A4 inhibitors [2].

Efficacy Context

The three key phase 3 trials (VIOLET, DAISY, and BEGONIA) each enrolled premenopausal women with HSDD over 24 weeks. Pooled data showed flibanserin increased satisfying sexual events by approximately 0.5 per month over placebo and reduced distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) [7]. The effect size is modest by any standard. Clinicians and patients should weigh this modest benefit directly against the meaningful hypotension risk, especially if the patient drinks alcohol regularly.

Other Drugs That Share the Interaction Mechanism

Alcohol is not the only agent that dangerously interacts with flibanserin through the hypotension-plus-CYP-inhibition pathway. The FDA label lists several categories as either contraindicated or requiring dose adjustment [3]:

Contraindicated CYP3A4 Inhibitors

Strong CYP3A4 inhibitors are contraindicated with flibanserin. These include:

• Ketoconazole (raises flibanserin AUC approximately 4.5-fold)
• Itraconazole
• Clarithromycin
• Nefazodone
• Ritonavir and other HIV protease inhibitors

The FDA label states: "Concomitant use of Addyi with moderate or strong CYP3A4 inhibitors will increase flibanserin exposure and the risk for hypotension, syncope, and CNS depression" [3].

Moderate CYP3A4 Inhibitors

Moderate inhibitors such as fluconazole, oral contraceptives containing norgestimate and ethinyl estradiol (which raised flibanserin AUC by approximately 2-fold in dedicated studies), and grapefruit juice require clinical assessment before co-prescribing [3].

CNS Depressants

Benzodiazepines, opioids, sedating antihistamines, and other CNS depressants all add to the pharmacodynamic hypotension and sedation risk, even without affecting CYP3A4.

Bedtime Dosing as a Risk Reduction Strategy

The recommended dose of flibanserin is 100 mg taken orally at bedtime. This timing was chosen specifically to reduce the impact of the drug's blood pressure-lowering effect during waking hours [3].

If a patient takes the drug at bedtime and peak plasma concentrations occur around 45 minutes to 1 hour post-dose (median Tmax 0.75 hours) while the patient is asleep, the hypotensive nadir coincides with the supine position, which partly buffers the hemodynamic effect [3]. Standing rapidly from sleep while flibanserin is still near peak concentration, however, still carries orthostatic hypotension risk. Patients should be counseled to rise slowly if they wake during the first 4 hours after dosing.

What Happens If a Dose Is Missed

A dose missed on a given night should be skipped entirely. Taking a missed dose the following morning moves the peak concentration window to daytime, when the patient is upright and ambulatory, dramatically increasing syncope risk. The same prohibition on alcohol applies on the day the dose would have been taken [3].

Practical Patient Instructions for Alcohol Avoidance

Patients often ask whether they can have a single drink at a social event while on flibanserin. The answer requires specificity rather than a blanket "yes" or "no." Below are the key practical points to review at every prescribing visit:

On the Day of Dosing

No alcohol. This includes beer, wine, liquor, and alcohol-containing medications such as cough syrups. Zero is the threshold, not "one drink is probably fine."

If Alcohol Is Anticipated

If a patient plans to attend an event where alcohol is expected, she has two evidence-aligned options. She may skip the flibanserin dose that night and resume the following night, accepting that HSDD treatment efficacy depends on nightly dosing and a single missed dose does not permanently affect the therapeutic benefit. Alternatively, she may abstain from alcohol completely at the event [3].

Driving and Operating Machinery

Even without alcohol, flibanserin may cause somnolence and dizziness. The combination further impairs psychomotor function. Patients should not drive or operate heavy machinery for at least 6 hours after taking flibanserin, and this window extends unpredictably when alcohol is also consumed [3].

Monitoring and Follow-Up After Starting Flibanserin

The bedtime dose and the alcohol prohibition are not "set and forget" counseling points. Monitoring should include:

• Blood pressure assessment at the first follow-up visit (4 to 8 weeks after initiation).
• Review of any syncope or near-syncope episodes.
• Reassessment of concomitant medications, including any newly started oral contraceptives or antifungals.
• Screening for alcohol use using a validated tool such as the AUDIT-C at each visit, given that alcohol use disorders affect approximately 5.3% of adult women in the United States [8].

When to Discontinue

The FDA label recommends discontinuing flibanserin if the patient has not had an improvement in HSDD symptoms after 8 weeks at the recommended dose of 100 mg nightly [3]. This 8-week trial period also provides a natural decision point to reassess the patient's ability to maintain alcohol abstinence.

Special Populations

Hepatic Impairment

Flibanserin is contraindicated in patients with hepatic impairment. Because the liver is the primary site of CYP3A4 and CYP2C19 metabolism, any reduction in hepatic function raises baseline flibanserin exposure substantially. Alcohol itself causes hepatic impairment acutely and chronically, providing another biological pathway through which alcohol use worsens flibanserin's safety profile [3].

Postmenopausal Women

Flibanserin is FDA-approved only for premenopausal women with HSDD [2]. Use in postmenopausal women is off-label. The alcohol interaction data were collected in premenopausal study populations, and any extrapolation to older women who may have lower basal vasomotor tone and greater cardiovascular comorbidities should be made with even more caution.

Summary of the Interaction in Numbers

The key data points clinicians and patients should retain:

• 17% rate of severe hypotension when flibanserin 100 mg was combined with 0.5 g/kg alcohol in the dedicated interaction study (N=23) [4].
• 0.5 g/kg alcohol equals approximately 2 standard drinks for a 60 kg woman, per the CDC standard drink definition of 14 g ethanol [5].
• 11-hour mean elimination half-life of flibanserin, informing the minimum abstinence window [3].
• 7-fold increase in flibanserin AUC with the strong CYP3A4 inhibitor fluconazole, illustrating enzyme-inhibition sensitivity [3].
• 8-week trial period before discontinuation if no symptomatic benefit is observed [3].

Patients who cannot reliably abstain from alcohol on dosing days should have a direct conversation with their prescriber about whether flibanserin is the appropriate choice given their drinking pattern, and whether non-pharmacologic interventions for HSDD should be tried first.